Management of immune-mediated cytopenias in pregnancy

Caroline I. Piatek, Ihab El-Hemaidi, Donald I. Feinstein, Howard A. Liebman, Mojtaba Akhtari

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Immune-mediated cytopenias are a well-described complication of pregnancy. Appropriate recognition and treatment are important in order to limit maternal and fetal morbidity and mortality. First line treatment options are fairly well-established for these entities. Refractory disease may be difficult to manage because treatment choices are limited by known or unestablished risk to the fetus. While the use of new agents, such as romiplostim and rituximab, has been reported, their safety in pregnancy is not known. This article summarizes immune cytopenias seen in pregnant patients, and it also discusses management of these cytopenias, and provides practical strategies for the treatment of these challenging conditions.

Original languageEnglish (US)
Pages (from-to)806-811
Number of pages6
JournalAutoimmunity Reviews
Volume14
Issue number9
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Pregnancy
Fetal Mortality
Pregnancy Complications
Therapeutics
Fetus
Mothers
Morbidity
Safety
Rituximab
romiplostim

Keywords

  • Autoimmune hemolytic anemia
  • Autoimmune neutropenia
  • Immune thrombocytopenia
  • Pregnancy
  • Thrombotic thrombocytopenia purpura

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Piatek, C. I., El-Hemaidi, I., Feinstein, D. I., Liebman, H. A., & Akhtari, M. (2015). Management of immune-mediated cytopenias in pregnancy. Autoimmunity Reviews, 14(9), 806-811. https://doi.org/10.1016/j.autrev.2015.05.003

Management of immune-mediated cytopenias in pregnancy. / Piatek, Caroline I.; El-Hemaidi, Ihab; Feinstein, Donald I.; Liebman, Howard A.; Akhtari, Mojtaba.

In: Autoimmunity Reviews, Vol. 14, No. 9, 01.09.2015, p. 806-811.

Research output: Contribution to journalArticle

Piatek, CI, El-Hemaidi, I, Feinstein, DI, Liebman, HA & Akhtari, M 2015, 'Management of immune-mediated cytopenias in pregnancy', Autoimmunity Reviews, vol. 14, no. 9, pp. 806-811. https://doi.org/10.1016/j.autrev.2015.05.003
Piatek CI, El-Hemaidi I, Feinstein DI, Liebman HA, Akhtari M. Management of immune-mediated cytopenias in pregnancy. Autoimmunity Reviews. 2015 Sep 1;14(9):806-811. https://doi.org/10.1016/j.autrev.2015.05.003
Piatek, Caroline I. ; El-Hemaidi, Ihab ; Feinstein, Donald I. ; Liebman, Howard A. ; Akhtari, Mojtaba. / Management of immune-mediated cytopenias in pregnancy. In: Autoimmunity Reviews. 2015 ; Vol. 14, No. 9. pp. 806-811.
@article{38b6a81ca3ac4926bf2841516d30d844,
title = "Management of immune-mediated cytopenias in pregnancy",
abstract = "Immune-mediated cytopenias are a well-described complication of pregnancy. Appropriate recognition and treatment are important in order to limit maternal and fetal morbidity and mortality. First line treatment options are fairly well-established for these entities. Refractory disease may be difficult to manage because treatment choices are limited by known or unestablished risk to the fetus. While the use of new agents, such as romiplostim and rituximab, has been reported, their safety in pregnancy is not known. This article summarizes immune cytopenias seen in pregnant patients, and it also discusses management of these cytopenias, and provides practical strategies for the treatment of these challenging conditions.",
keywords = "Autoimmune hemolytic anemia, Autoimmune neutropenia, Immune thrombocytopenia, Pregnancy, Thrombotic thrombocytopenia purpura",
author = "Piatek, {Caroline I.} and Ihab El-Hemaidi and Feinstein, {Donald I.} and Liebman, {Howard A.} and Mojtaba Akhtari",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.autrev.2015.05.003",
language = "English (US)",
volume = "14",
pages = "806--811",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Management of immune-mediated cytopenias in pregnancy

AU - Piatek, Caroline I.

AU - El-Hemaidi, Ihab

AU - Feinstein, Donald I.

AU - Liebman, Howard A.

AU - Akhtari, Mojtaba

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Immune-mediated cytopenias are a well-described complication of pregnancy. Appropriate recognition and treatment are important in order to limit maternal and fetal morbidity and mortality. First line treatment options are fairly well-established for these entities. Refractory disease may be difficult to manage because treatment choices are limited by known or unestablished risk to the fetus. While the use of new agents, such as romiplostim and rituximab, has been reported, their safety in pregnancy is not known. This article summarizes immune cytopenias seen in pregnant patients, and it also discusses management of these cytopenias, and provides practical strategies for the treatment of these challenging conditions.

AB - Immune-mediated cytopenias are a well-described complication of pregnancy. Appropriate recognition and treatment are important in order to limit maternal and fetal morbidity and mortality. First line treatment options are fairly well-established for these entities. Refractory disease may be difficult to manage because treatment choices are limited by known or unestablished risk to the fetus. While the use of new agents, such as romiplostim and rituximab, has been reported, their safety in pregnancy is not known. This article summarizes immune cytopenias seen in pregnant patients, and it also discusses management of these cytopenias, and provides practical strategies for the treatment of these challenging conditions.

KW - Autoimmune hemolytic anemia

KW - Autoimmune neutropenia

KW - Immune thrombocytopenia

KW - Pregnancy

KW - Thrombotic thrombocytopenia purpura

UR - http://www.scopus.com/inward/record.url?scp=84938216455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938216455&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2015.05.003

DO - 10.1016/j.autrev.2015.05.003

M3 - Article

VL - 14

SP - 806

EP - 811

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 9

ER -